Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Support—Results of a Prospective, Randomized, Comparative Study

Table 1

Patient demographics and stimulation parameters (mean ± SD).

	Group A; (buserelin 3x/day)	Group B; (micronized progesterone 3x/day)
Age (years)	32 ± 4.4	33 ± 4.5	NS
Range	2 ± 1.1	2 ± 1.3	NS
HMG (IU)	2526 ± 988	2614 ± 1077	NS
Day of trigger (=D0)	12.7 ± 2.7	12.9 ± 2.6	NS
Estradiol D0 (pg/mL)	2960 ± 1068	2929 ± 1439	NS
Progesterone D0 (ng/mL)	0.9 ± 0.4	1 ± 0.4	NS
Endometrial thickness D0 (mm)	9.8 ± 2.1	9.0 ± 3.0	NS